

Genomeditech (Shanghai) Co.,Ltd. Order: +86 021-68455258/50432826/50432825 Toll-free: +86 400 627 9288 Email: service@genomeditech.com

# **Product Sheet**

## H\_IL7R CHO-K1 Cell Line

Catalog number: GM-C39199

Version 3.3.1.250613

Description	H_IL7R CHO-K1 Cell Line is a clonal stable CHO-K1 cell line that constitutively expresses the human IL7R gene, constructed using lentiviral technology.	
Quantity	5E6 Cells per vial,1 mL	
Product Format	uct Format 1 vial of frozen cells	
Shipping	Shipped on dry ice	
Storage Conditions	Liquid nitrogen immediately upon receipt	
Target	Human_IL7R	
Gene ID/Uniprot ID	P16871-1(AA Met 1 - Trp 264)	
Host Cell	СНО-К1	
Recovery Medium	F12K+10% FBS+1% P.S	
Growth medium	F12K+10% FBS+1% P.S+4 µg/mL Puromycin	
Note	None	
Freezing Medium	90% FBS+10% DMSO	
Growth properties	Adherent	
Growth Conditions	37°C, 5% CO <sub>2</sub>	
Mycoplasma Testing	ycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.	
Safety considerations	Biosafety Level 2	
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.	



Genomeditech (Shanghai) Co., Ltd. Order: +86 021-68455258/50432826/50432825 Toll-free: +86 400 627 9288 Email: service@genomeditech.com

### **Materials**

Reagent	Manufacturer/Catalogue No.
F12K	BOSTER/PYG0036
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
Pen/Strep	Thermo/15140-122
Puromycin	Genomeditech/GM-040401
Anti-H_IL-7Rα hIgG4 Antibody(lusvertikimab)	Genomeditech/GM-32425AB

## **Figures**





Figure 1 | H\_IL7R CHO-K1 Cell Line (Cat. GM-C39199) was determined by flow cytometry using Anti-H\_IL-7Rα hIgG4 Antibody(lusvertikimab) (Cat. GM-32425AB).



SampleID	Geometric Mean : FL11-H
CHO-K1 anti-IL-7Ra+APC-2nd Ab	1521
CHO-K1 H_IL7R H_IgG+APC-2nd Ab	1075
CHO-K1 H_IL7R anti-IL-7Ra+APC-2nd Ab CP3	9.90E5
CHO-K1 H_IL7R anti-IL-7Ra+APC-2nd Ab CP13	1.12E6
CHO-K1 H IL7R anti-IL-7Ra+APC-2nd Ab CP23	1.01E6

Figure 2 | The passage stability of the H\_IL7R CHO-K1 Cell Line (Cat. GM-C39199) was determined by flow cytometry using Anti-H\_IL-7Rα hIgG4 Antibody(lusvertikimab) (Cat. GM-32425AB).

> Genomeditech (Shanghai) Co., Ltd 吉满生物科技(上海)有限公司

上海市浦东新区康威路 299 号 1 幢东区 505-507 邮编 201315 505-507,5th Floor, East District, Building 1,No.299 Kangwei Road, Pudong New Area, Shanghai 本公司产品仅供科研用途,严禁用于人体治疗! For research use only!



## **Cell Recovery**

Recovery Medium: F12K+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at  $-70^{\circ}$ C. Storage at  $-70^{\circ}$ C will result in loss of viability.

- a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 3 minutes).
- b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
- d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO<sub>2</sub> in air atmosphere is recommended if using the medium described on this product sheet.

## **Cell Freezing**

Freezing Medium: 90% FBS+10% DMSO

- a) Centrifuge at 176 x g for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

## Cell passage

Growth medium: F12K+10% FBS+1% P.S+4 µg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

- a) Remove and discard culture medium.
- b) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
- c) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 2 to 3 minutes at 37°C).
- Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach.
  Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- e) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
- f) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
- g) Incubate cultures at 37°C.

#### Subcultivation Ratio: A subcultivation ratio of 1:4 - 1:5 is recommended

吉满生物科技(上海)有限公司 Genomeditech (Shanghai) Co., Ltd

上海市浦东新区康威路 299 号 1 幢东区 505-507 邮编 201315 505-507,5th Floor, East District, Building 1,No.299 Kangwei Road, Pudong New Area, Shanghai 本公司产品仅供科研用途,严禁用于人体治疗! For research use only!



#### Medium Renewal: Every 2 to 3 days

## Notes

a) After the stabilization of the cell condition, there will be fewer dead cells post-passage, the cell growth rate will tend to stabilize, cell morphology will become uniform, and the cells will appear robust.

## Sequence

IL7R P16871-1 ( \( \Lambda \) ICD )

MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEI CGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFV VTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFW SEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLW\*

## **Related Products**

IL-7		
H_IL-7 Reporter Cell Line	H_IL7R HEK-293 Cell Line	
Anti-H_IL-7Ra hIgG4 Antibody(lusvertikimab)	Anti-IL7Ra hIgG1 Antibody(4A10)	

## Limited Use License Agreement

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.